Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Davis Polk guides pharmaceutical sector acquisition

27 August 2026 · By · Wire by Fusion42

Published

27 August 2026

Topic

opportunities

◆ Sectors

Health

◆ Geography

United States

◆ Source

Read at iclg.com →

◆ Verified

Fusion42 · 27 August 2026 · Fusion42 review

Davis Polk advised McKesson on a $2.25 billion deal to acquire Precision Medicine Group, enhancing McKesson’s clinical research and biopharma commercialisation capabilities in the US healthcare sector.

This Wire brief sits within Fusion42's coverage of Health.

◆ ◆ The Wire takeaway

Pharma and clinical research founders should note McKesson’s new capability boost; your clients now have a bigger player improving trial execution and commercialisation you will compete against or partner with.

◆ Coverage

1 source · 27 Aug 2026

◆ Related on Wire

◆ Topics

Healthpharmaceutical-maclinical-researchbiopharmahealthcare-servicesmckesson